Log In
BCIQ
Print this Print this
 

Soliqua, Suliqua, Lixisenatide/insulin glargine (iGlarLixi, LixiLan)

Also known as: Lixisenatide/ZP10+Lantus

  Manage Alerts
Collapse Summary General Information
Company Zealand Pharma A/S
DescriptionFixed-dose combination of Lantus insulin glargine, a synthetic sustained-release subcutaneous insulin analog, and Lyxumia lixisenatide, a glucagon-like peptide-1 receptor (GLP-1R; GLP1R) agonist
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) ; Insulin receptor (INSR)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist; Insulin receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation U.S. - Priority Review (Treat Type II diabetes)
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today